Pinometostat

Drug Profile

Pinometostat

Alternative Names: EPZ-5676

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Epizyme
  • Class Antineoplastics; Benzimidazoles; Cyclobutanes; Furans; Purines; Small molecules
  • Mechanism of Action DOT1L protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Leukaemia; Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Leukaemia

Most Recent Events

  • 31 Oct 2016 Epizyme establishes CRADA with National Cancer Institute (USA) for the development of pinometostat in Acute leukaemias
  • 31 Oct 2016 Epizyma and National Cancer Institute (USA) plan a clinical trial for Acute leukaemia in USA
  • 01 Jun 2016 Epizyme completes phase-I clinical trials in Leukaemia (In adolescents, In children, In infants) in USA and Canada (IV) (NCT02141828)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top